Davare Lab

@Moranaaa @RutgersCancer @RWJBarnabas @Moranaaa @ChrisFebres Fantastic collaboration, Thank you! Our paper gets to the crux of the formidable clinical challenge posted by #GBM and yet second line targeted options should not be discounted.

It is with great honor that I share our most recent publication, exploring actionability of acquired #PDGFRA fusions in #GBM. We show evidence of clonal sweep after exposure to an #EGFR monoclonal antibody and successful targeting of the newly acquired MDM2-PDGFRA fusion. This emphasizes the importance of repeat #NGS in patients with recurrent #GBM, evolution of #glioblastoma through several rounds of therapy and proactive monitoring and treatment through its evolution. Thank you to all my collaborators! @DavareLab @ChrisFebres @RandyDAmico_MD @johnboockvar @tamikawong1163 @JLG_Marti @SaeedAsiry @NaturePortfolio @Nature_NPJ @NeuroOnc nature.com/articles/s4169…

@TejasPatilMD @lcsmchat @OncoAlert Thanks, Tejas!

👏🏽A very wise and important insight!!! @lcsmchat @OncoAlert

@MLadanyi Thank you, Marc!

Most negative results remain unpublished, creating blind spots in AI training and risking suggestions of already-failed ideas. AI can transform science—but only if it sees the full record of scientific successes and failures. nature.com/articles/d4158… #AI #OpenScience #scicomm

@RobertKennedyJr @RobertKennedyJr Happy to see your support! Hope NIH will continue to support rigorous basic and translational research for rare cancers, including childhood cancers.

@peterfenton @wgibson Lets cure these rare sarcomas! If you know someone with myxoid leimyosarcoma please reach out to @wgibson.

My sister’s been diagnosed with a rare sarcoma, motivating this search for look-a-like cases if you know anyone please let @wgibson know, his lab at Dana-Farber looks and feels like the best startups in the silicon valley they will change the future of cancer

@VPrasadMDMPH You make some good points. Reproducibility is a serious issue in our field. So garbage in, garbage out is a liability of this approach. We need to invest more in rigorous basic science research to generate quality datasets for AI training to maximize potential.

AI will do a lot of good things. But it won't cure cancer. Here are a few reasons why 1. AI is trained on the best available published literature. If you have AI read all of the papers in cancer, you have just had AI read 50% or more of literature that cannot be reproduced or may even be fraudulent. If you have AI restrict itself to reading nature science cell JBO, AI has still trained on 50% of material that will not replicate, and is not true. How can AI solve the problem when you pump it full of false information? 2. There is no way to separate the false information from the true information unless you replicate the experiments. That requires beakers pipettes dishes and hands. Now Maybe if AI has a robot form and starts replicating things now you're talking. 3. The limit with cancer cures is is not that we are not reading and synthesizing all the available materials. There are a lot of very smart people working in this space, and they do read widely and think about always all possible ways to combine different strategies. Instead, the limit is biology itself. Understanding what is happening in the cell that has not been seen or detected in current experiments. AI has no way to do this unless it again picks up a pipette. 4. Some of the things people celebrate today to like AI can find more lesions on mammograms. It just reveals the ignorance of the technology people. What is a lesion on a mammogram? It's something that when you stick a needle in it according to a pathologist it has basement invasion. So it looks like cancer under the microscope. this is what AI is being trained on. But it has nothing to do with whether or not the lesion you see is going to progress in your natural life, and kill you, whether or not it's going to stay dormant, whether or not it's spread already. You want to find lesions that are going to kill you. But you can cut out today. We don't know which lesions those are! AI is being trained on a faulty data set yet again. I described this at length in a recent plenary session lecture. 5. 20 years ago they said Judah folkman was going to cure cancer. Then they said immunotherapy was going to cure all cancer. I guess the difference between folkman and immunotherapy is at least immunotherapy has cured some people but folkman cured about zero people. 10 years ago the hype was all about personalized sequencing. Now the hype is AI. There's always going to be some hype. You're better off not smoking, keeping your weight down, exercising and then just accepting that immortality is not going to be happening. Side note: it's probably a good thing that people are not immortal. People need to die so that their terrible ideas can be replaced with slightly less terrible ideas. Certainly there are backslides, but such is the nature of progress. Reducing untimely death is a much better goal than making people live to 120.

@wgibson @DrSarcoma @DavareLab thrilled to partner with the group for tackling this rare cancer!

Seeking patients with myxoid leiomyosarcoma featuring a PLAG1 fusion. We're forming a major foundation with the best minds including @drsarcoma to find treatments and a cure for this rare disease, including developing in-vitro tumor models. Know someone affected? Pls reach out!

“When I met Dr. Cetnar, he had an associate who was doing research with ROS1. They told me my diagnosis, explained everything about it, and gave me so much relief and hope I said, ‘Can I hug both of you? You both gave me my life back.’" Clare's story: bit.ly/4fVcP8J

@TejasPatilMD @ros1cancer Thanks, Tejas!

Fantastic work from @DavareLab on oncogenic potential of #ROS1 extracellular domain (ECD) which doesn’t necessarily require fusion partner to sustain oncogenesis. @ros1cancer

Loss of ROS1's extracellular domain may suffice for catalytic activation. However, the 5' fusion partner's promoter/enhancer will be required to drive its expression in diverse cancer cell lineages, as ROS1 expression is normally highly restricted in most adult human tissues.

ROS1 researchers & enthusiasts! Check our new paper: loss of ROS1's extracellular domain alone drives oncogenic activity, no N-terminal fusion partner needed. Dreaming of future cryo-EM studies... funding willing! nature.com/articles/s4159…

@OHSUKnight @KuniFoundation Gratitude for the Kuni Foundation for recognizing this gap! We are excited to partner with up @OHSUOrtho @OHSUKnight @OHSUDoernbecher colleagues on this meaningful project. @PapeOhsu

“This effort fills a critical gap in pediatric oncology and will accelerate effective treatments for youth impacted by these devastating bone cancers.” - @KuniFoundation president Angela Hult: bit.ly/3AAHSYw

Read out manuscript "TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers" in @Nature_NPJ This collaborative work from @DavareLab @alexdrilon shows data on the use of type II TKIs in ROS1 fusion cancers with L2086F mutation nature.com/articles/s4169…

@MLadanyi 👏

PDX vs. original tumor in childhood cancer👇

@juliamaxson Unruly felines who love typing 777rrhs13ty etc. in the middle of important drafts! 😀

@DavareLab Do you also have an unruly hound?

Why don’t I work from home more…exhibit A—60 lb hound in lap 👇